TheraRadar
← Back
Data updated: Jun 28, 2026

LANNETT CO INC

Generics

LANNETT CO INC is a generic drug manufacturer focused on Infectious Disease, Cardiovascular, Gastroenterology.

1955
Since
102
Drugs
-
Trials
1
New Drugs (2yr)
Modality:
1 Small Molecules

LANNETT CO INC's Key Drugs

LANNETT CO INC's core commercial portfolio centers on BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE, LOPINAVIR AND RITONAVIR, spanning Infectious Disease and Cardiovascular — its most strategically important drugs approved in the last 15 years.

LANNETT CO INC's Therapeutic Areas

LANNETT CO INC's approved drugs and pipeline span 5 therapeutic areas, led by Infectious Disease and Cardiovascular, across 0 biologic and 1 small-molecule drug. Weighted by commercial stage — approved drugs count most, then late-stage trials.

Infectious Disease 28%
6 drugs
Cardiovascular 24%
5 drugs
Gastroenterology 24%
5 drugs
Neurology 14%
3 drugs
Metabolic 10%
2 drugs Phase 1: 1

LANNETT CO INC's Top Competitors

LANNETT CO INC's closest competitors by therapeutic-area and drug-target overlap include Merck, Novo Nordisk, and Baxter. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.

LANNETT CO INC Pipeline Snapshot

LANNETT CO INC has 1 active clinical program from ClinicalTrials.gov — 0 Phase 3, 0 Phase 2 and 1 Phase 1.

0
Phase 3
0
Phase 2
1
Phase 1

Pro Intelligence Preview

Deep insights for investors and analysts

Revenue Insights

  • BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE leads revenue
  • 2 key drugs tracked

Trial Catalysts

  • Infectious Disease pipeline focus
  • Phase 3 readout tracking

Patent Risk

  • Patent expiration timeline
  • Revenue at risk analysis

Compare Companies

  • Side-by-side pipeline analysis
  • Revenue & market share comparison
Unlock Full Intelligence

Revenue forecasts • Trial milestones • Patent risk modeling